News Tag: Regulatory
-
Interim Report for Ortivus AB (publ) for the period January – March 2025
“Our ambition is not only to deliver technology, but to be a strategic partner in the transformation of healthcare.”
-
Correction: The Board of Directors of Ortivus AB withdraws the proposal to the Annual General Meeting on 8 May 2025 regarding authorisation for the Board to issue shares, etc.
The Board of Directors of Ortivus AB has resolved to withdraw its proposal that the Board be granted authorisation by the Annual General Meeting to issue class B shares, etc. The proposal is withdrawn in its entirety.
-
Ortivus: Year-end report January-December 2024
During the year, we have carried out extensive organisational changes and strengthened our team to support our growth journey. Additionally, we have implemented a new business system to improve financial control and the monitoring of our key metrics.
-
Ortivus will change its listing to Nasdaq First North Growth Market on December 19, 2024
Ortivus AB (publ) (“Ortivus” or the “Company”) has applied for and today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market will be December 19, 2024.
